Manual IVF Screening May Miss Additional Oocytes - Scorecard - MDSpire

Manual IVF Screening May Miss Additional Oocytes

Clinical study suggests automated system can recover mature oocytes overlooked during standard screening

  • By

  • Henry Thomas

  • February 18, 2026

  • 3 min

Share

Clinical Scorecard: Manual IVF Screening May Miss Additional Oocytes

At a Glance

CategoryDetail
ConditionIn Vitro Fertilization (IVF)
Key MechanismsAutomated microfluidic device (FIND-Chip) for oocyte recovery
Target PopulationPatients undergoing IVF, particularly those with diminished ovarian reserve
Care SettingIVF centers

Key Highlights

  • Manual screening may overlook additional mature oocytes capable of fertilization.
  • FIND-Chip recovered 583 additional oocytes from discarded samples.
  • Over 40% of recovered oocytes were mature metaphase II oocytes.
  • Some recovered oocytes led to high-quality embryos and a live birth.
  • Automated screening may enhance IVF laboratory efficiency.

Guideline-Based Recommendations

Diagnosis

  • Consider automated screening technologies for oocyte recovery.

Management

  • Integrate additional oocytes into patient treatment cycles.

Monitoring & Follow-up

  • Evaluate the developmental potential of recovered oocytes.

Risks

  • Potential variability in outcomes due to small sample sizes in studies.

Patient & Prescribing Data

582 patients across four IVF centers

Automated systems may improve oocyte yield and treatment outcomes.

Clinical Best Practices

  • Utilize automated devices to enhance oocyte recovery.
  • Standardize laboratory processes to improve IVF efficiency.
  • Monitor cumulative live birth rates in relation to oocyte recovery.

References

Original Source(s)

Manual IVF Screening May Miss Additional Oocytes

  • by Henry Thomas

  • February 18, 2026

Related Content

Type 1 Diabetes Shapes Pregnancy, Motherhood Experiences

Qualitative study highlights concerns about heredity, information gaps, and balancing diabetes management with parenting

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.